Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma

Cancer Science

Volumn 104, Issue 11, 2013, Pages 1411-1419

  Yamasaki, Takeshi ^a   Seki, Naohiko ^b   Yoshino, Hirofumi ^a   Itesako, Toshihiko ^a   Yamada, Yasutoshi ^a   Tatarano, Shuichi ^a   Hidaka, Hideo ^a   Yonezawa, Tomokazu ^a   Nakagawa, Masayuki ^a   Enokida, Hideki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; MICRORNA; MICRORNA 1291; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SLC2A1 GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLUCOSE TRANSPORTER TYPE 1; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; RNA INTERFERENCE; TRANSCRIPTOME;

EID: 84886791759     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12240     Document Type: Article

References (35)

1. Gupta K, Miller JD, Li JZ et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008; 34: 193-205.
2. Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol 2010; 4: 143-54.
3. Griffioen AW, Mans LA, de Graaf AM et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012; 18: 3961-71.
4. Mattick JS. RNA regulation: a new genetics? Nat Rev Genet 2004; 5: 316-23.
5. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-14.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
7. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 2008; 7: 3655-60.
8. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
9. Hidaka H, Seki N, Yoshino H et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012; 3: 44-57.
10. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
11. Gogvadze V, Zhivotovsky B, Orrenius S. The Warburg effect and mitochondrial stability in cancer cells. Mol Aspects Med 2010; 31: 60-74.
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
13. Sommermann TG, O'Neill K, Plas DR et al. IKKβ and NF-κB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res 2011; 71: 7291-300.
14. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 6th edn. International Union Against Cancer (UICC). New York: Wiley-Liss Inc., 2009; 255-257.
15. Chiyomaru T, Enokida H, Tatarano S et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102: 883-91.
16. Nohata N, Hanazawa T, Kikkawa N et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 2011; 38: 209-17.
17. Kawakami K, Enokida H, Chiyomaru T et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2012; 48: 827-36.
18. Davis-Dusenbery BN, Hata A. MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer 2010; 1: 1100-14.
19. Yamasaki T, Seki N, Yamada Y et al. Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol 2012; 41: 805-17.
20. Yamada Y, Hidaka H, Seki N et al. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci 2013; 104: 304-12.
21. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654-62.
22. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 2001; 18: 247-56.
23. North PE, Waner M, Mizeracki A et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22.
24. Ozcan A, Shen SS, Zhai QJ et al. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am J Clin Pathol 2007; 128: 245-54.
25. Nagase Y, Takata K, Moriyama N et al. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995; 153: 798-801.
26. Jang SM, Han H, Jang KS et al. The glycolytic phenotype is correlated with aggressiveness and poor prognosis in invasive ductal carcinoma. J Breast Cancer 2012; 15: 172-80.
27. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72: 2979-85.
28. Mellanen P, Minn H, Grenman R et al. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994; 56: 622-9.
29. Kawamura T, Kusakabe T, Sugino T et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis and patient survival. Cancer 2001; 92: 634-41.
30. Rudlowski C, Becker AJ, Schroder W et al. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol 2003; 120: 691-8.
31. Cantuaria G, Fagotti A, Ferrandina G et al. GLUT1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001; 92: 1144-50.
32. Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
33. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673-82.
34. Smaldone MC, Maranchie JK. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol 2009; 27: 238-45.
35. Chan DA, Sutphin PD, Nguyen P et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011; 3: 94ra70.